

March 30, 2017

DCI Partners Co., Ltd.

The founding of a new biotech company

「J-mab Therapeutics, Inc.」

DCI Partners Co., Ltd. (a group company of Daiwa Securities Group, Inc. and wholly owned by Daiwa Corporate Investment Co., Ltd.), managing one of the largest biotech funds in Japan named Daiwa Taiwan-Japan Biotech Fund with an aggregate fund size of 11.6 billion yen (the “Fund”), is pleased to announce that the Fund takes the initiative to launch a new company named J-mab Therapeutics, Inc. (“J-mab”), and the new company has achieved a license agreement with Juntendo University and RIKEN¹. J-mab was founded to accelerate R&D of antibodies invented by Dr. Shuji Matsuoka, department of pathology and oncology in Juntendo University School of Medicine, Tokyo Japan, and supported by research teams of RIKEN for the identification of their target molecules. The antibodies could induce a novel type of cell death to malignant lymphoma cells but not normal cells, indicating that they would potentially become new cancer therapeutic drugs without adverse effects.

1. Overview

The antibodies are created based on the research results of department of pathology and oncology in Juntendo University School of Medicine and RIKEN Center for Integrative Medical Sciences and Program for Drug Discovery and Medical Technology Platforms. Two unique activities of the antibodies are characterized, of which one is that the antibodies can directly and rapidly destroy cancer cells without any aids of inherent immune systems such as ADCC or CDC, and the other is that they would show a positive medical performance on the recurrent cancer even with resistant strains’ appearance, suggesting that there exist possibilities to provide new therapeutic agents to patients with malignant lymphoma and adult T cell leukemia and patients who have relapsed which could not be treated with conventional anticancer drugs or molecular targeted drugs.


The Fund is a venture capital fund that invests in privately-held biotechnology companies centered on the therapeutic field in Japan and Taiwan. In addition to investments into existing biotechnology companies, the Fund is also actively engaged in a launch of new startups, known as “Venture Creation Investment”. J-mab is the first case in Venture Creation Investment in Japan.

Press Release

The new company has also signed a contract of receiving a capital of approximately 1 billion yen with Nissay Capital No. 7 Investment Limited Partnership ("Nissay 7") managed by Nissay Capital Co., Ltd., as well as the Fund. Moreover, in addition to funding over R&D expenditures, the Fund will also commit to provide hands-on support by actively liaising with advisors who possess expertise in the areas such as drug development, licensing, regulatory affairs and business development, in order to facilitate R&D progress in the new company.

The Fund will continuously source attractive seeds and make best effort to contribute to the development of health care and pharmaceutical industries in Japan and Taiwan.

2. Overview of Business Scheme



Overview of the Fund

Name	Daiwa Taiwan-Japan Biotech Fund Investment Limited Partnership
Date of Establishment	January 15, 2015
Total Committed Capital	JPY 11.6 billion
General Partner (GP)	DCI Partners Co., Ltd.
Main Limited Partners	<ul style="list-style-type: none"> Organization for Small & Medium Enterprises and Regional Innovation, JAPAN National Development Fund, Executive Yuan

Press Release

Overview of DCI Partners

Name	DCI Partners Co., Ltd.
Date of Establishment	May 20, 2014
Share Capital	JPY 50 million
Head Office	1-9-1, Marunouchi, Chiyoda-ku, Tokyo
Shareholder	Daiwa Corporate Investment Co., Ltd. (100%)
President & CEO	Hiroki Narita

3. Contact

For further information, please contact

DCI Partners Co., Ltd. : Narita, Kodama, Yokota (+81-3-5555-6337)

ⁱ RIKEN : Japan's largest and most comprehensive research organization for basic and applied science and a world leader in a diverse array of scientific disciplines. Source: <http://www.riken.jp/en/>